ISRCTN BASIC RESULTS

MERS003 (ISRCTN17936606)

Study Title: A phase I study to determine the safety and immunogenicity of a new vaccine against Middle East Respiratory Syndrome Coronavirus in Adults aged 50 to 70

Sponsor: University of Oxford

Funder: CEPI

REC Details: South Central - Oxford A Research Ethics Committee

REC Number: 23/SC/0047

EudraCT Number: 2022-002159-21

IRAS Reference: 1006223

1. PARTICIPANT FLOW 2

2. BASELINE CHARACTERISTICS 3

3. PRIMARY OUTCOMES 4

3.1 Occurrence of solicited local reactogenicity signs and symptoms and occurrence of solicited systemic reactogenicity signs and symptoms 5

Summary of maximum severity of solicited adverse events during days 0-6 after each vaccination 6

Maximum severity of solicited adverse events during days 0-6 after first vaccination: group 1 7

Maximum severity of solicited adverse events during days 0-6 after second vaccination: group 1 9

Maximum severity of solicited adverse events during days 0-6 after first vaccination: group 2 11

Maximum severity of solicited adverse events during days 0-6 after second vaccination: group 2 13

3.2 Occurrence of unsolicited adverse events (AEs) 15

Summary of unsolicited AEs (excluding SAEs) 16

Summary of all unsolicited AEs (including any SAEs and AESIs) by MedDRA System Organ Class and Preferred Term 17

Summary of participants with unsolicited AEs (including SAEs and AESIs) by MedDRA System Organ Class and Preferred Term 20

3.3 Change from baseline for safety laboratory measures 23

Biochemistry results after first vaccination 24

Biochemistry results after second vaccination 30

Haematology results after first vaccination 36

Haematology results after second vaccination 40

3.4 SAEs and AESIs 44

Summary of SAEs 44

4. SECONDARY OUTCOMES 45

4.1 MERS spike protein specific serological response as measured by ELISA 46

Humoral results 46

Anti-spike MERS ELISA (EU) results 47

Anti-spike MERS ELISA (IU) results 47

Anti-spike MERS ELISA seroconversion 48

Geometric mean fold-rise (GMFR) results 50

4.2 MERS spike protein T cell response measured by IFN-γ ELISPOT 51

ELISpot results (SFC/10^6 PBMCs) 51

1. PARTICIPANT FLOW



2. BASELINE CHARACTERISTICS

All participants were recruited at the Liverpool School of Tropical Medicine, Liverpool, UK.

Demographic	Group 1		Group 2		All n=84[1]
	ChAdOx1 MERS n=37[1]	Placebo n=8[1]	ChAdOx1 MERS n=33[1]	Placebo n=6[1]	
Sex					
Female	14 (37.8%)	5 (62.5%)	19 (57.6%)	5 (83.3%)	43 (51.2%)
Male	23 (62.2%)	3 (37.5%)	14 (42.4%)	1 (16.7%)	41 (48.8%)
Age (years)	63.2 [57.7-65.9]	62.1 [60.6-65.5]	62.9 [57.0-66.3]	62.2 [60.0-65.0]	62.9 [58.0-66.1]
BMI	23.3 [21.9-29.7]	26.8 [26.4-29.1]	25.3 [23.6-30.7]	27.8 [23.7-33.9]	25.4 [23.0-30.0]
Ethnicity					
White	37 (100.0%)	7 (87.5%)	32 (97.0%)	4 (66.7%)	80 (95.2%)
Black	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Asian	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Mixed	0 (0.0%)	0 (0.0%)	1 (3.0%)	2 (33.3%)	3 (3.6%)
Arab	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Other[2]	0 (0.0%)	1 (12.5%)	0 (0.0%)	0 (0.0%)	1 (1.2%)
PNG/missing	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)	0 (0.0%)
Number of prior ChAdOx1 nCoV-19 vaccinations received prior to trial					
0			33 (100.0%)	6 (100.0%)	39 (46.4%)
1	0 (0.0%)	0 (0.0%)			0 (0.0%)
2	36 (97.3%)	7 (87.5%)			43 (51.2%)
3	1 (2.7%)	1 (12.5%)			2 (2.4%)

[1]n (%); median (IQR)

[2]Other ethnicity was reported as “Middle eastern”

3. PRIMARY OUTCOMES

Outcome	Objective	Outcome measure	Evaluation Timepoints*
Primary	To assess the safety and tolerability of ChAdOx1 MERS vaccine in healthy volunteers aged 50-70.	a) Occurrence of solicited local reactogenicity signs and symptoms	Within 7 days of each vaccination
		b) Occurrence of solicited systemic reactogenicity signs and symptoms	Within 7 days of each vaccination
		c) Occurrence of unsolicited adverse events (AEs)	Within 28 days of each vaccination
		d) Change from baseline for safety laboratory measures	Within 28 days of each vaccination
		e) SAEs and AESIs	Whole duration of the study follow up period (D0 to V2+281)

3.1 Occurrence of solicited local reactogenicity signs and symptoms and occurrence of solicited systemic reactogenicity signs and symptoms

Outcome measure	Evaluation Timepoints*
a) Occurrence of solicited local reactogenicity signs and symptoms	Within 7 days of each vaccination
b) Occurrence of solicited systemic reactogenicity signs and symptoms	Within 7 days of each vaccination

Summary of maximum severity of solicited adverse events during days 0-6 after each vaccination

Maximum severity	Group 1				Group 2			
	First vaccination		Second vaccination		First vaccination		Second vaccination	
	ChAdOx1 MERS	Placebo	ChAdOx1 MERS	Placebo	ChAdOx1 MERS	Placebo	ChAdOx1 MERS	Placebo
None	9/37 (24.32%; 11.77%-41.20%)	5/8 (62.50%; 24.49%-91.48%)	12/35 (34.29%; 19.13%-52.21%)	3/8 (37.50%; 8.52%-75.51%)	8/33 (24.24%; 11.09%-42.26%)	5/6 (83.33%; 35.88%-99.58%)	12/32 (37.50%; 21.10%-56.31%)	2/6 (33.33%; 4.33%-77.72%)
Mild	24/37 (64.86%; 47.46%-79.79%)	3/8 (37.50%; 8.52%-75.51%)	18/35 (51.43%; 33.99%-68.62%)	5/8 (62.50%; 24.49%-91.48%)	15/33 (45.45%; 28.11%-63.65%)	1/6 (16.67%; 0.42%-64.12%)	18/32 (56.25%; 37.66%-73.64%)	3/6 (50.00%; 11.81%-88.19%)
Moderate	4/37 (10.81%; 3.03%-25.42%)	0/8 (0.00%; 0.00%-36.94%)	5/35 (14.29%; 4.81%-30.26%)	0/8 (0.00%; 0.00%-36.94%)	7/33 (21.21%; 8.98%-38.91%)	0/6 (0.00%; 0.00%-45.93%)	2/32 (6.25%; 0.77%-20.81%)	1/6 (16.67%; 0.42%-64.12%)
Severe	0/37 (0.00%; 0.00%-9.49%)	0/8 (0.00%; 0.00%-36.94%)	0/35 (0.00%; 0.00%-10.00%)	0/8 (0.00%; 0.00%-36.94%)	3/33 (9.09%; 1.92%-24.33%)	0/6 (0.00%; 0.00%-45.93%)	0/32 (0.00%; 0.00%-10.89%)	0/6 (0.00%; 0.00%-45.93%)
Hospitalised	0/37 (0.00%; 0.00%-9.49%)	0/8 (0.00%; 0.00%-36.94%)	0/35 (0.00%; 0.00%-10.00%)	0/8 (0.00%; 0.00%-36.94%)	0/33 (0.00%; 0.00%-10.58%)	0/6 (0.00%; 0.00%-45.93%)	0/32 (0.00%; 0.00%-10.89%)	0/6 (0.00%; 0.00%-45.93%)
Any	28/37 (75.68%; 58.80%-88.23%)	3/8 (37.50%; 8.52%-75.51%)	23/35 (65.71%; 47.79%-80.87%)	5/8 (62.50%; 24.49%-91.48%)	25/33 (75.76%; 57.74%-88.91%)	1/6 (16.67%; 0.42%-64.12%)	20/32 (62.50%; 43.69%-78.90%)	4/6 (66.67%; 22.28%-95.67%)

Maximum severity of solicited adverse events during days 0-6 after first vaccination: group 1

Arm	Symptom	Maximum severity					
		None	Mild	Moderate	Severe	Hospitalised	Any
ChAdOx1 MERS	Redness	37/37 (100.00%; 90.51%-100.00%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)
	Warmth	31/37 (83.78%; 67.99%-93.81%)	6/37 (16.22%; 6.19%-32.01%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	6/37 (16.22%; 6.19%-32.01%)
	Itch	35/37 (94.59%; 81.81%-99.34%)	2/37 (5.41%; 0.66%-18.19%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	2/37 (5.41%; 0.66%-18.19%)
	Pain	17/37 (45.95%; 29.49%-63.08%)	20/37 (54.05%; 36.92%-70.51%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	20/37 (54.05%; 36.92%-70.51%)
	Swelling	37/37 (100.00%; 90.51%-100.00%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)
	Fever ≥38°C	37/37 (100.00%; 90.51%-100.00%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)
	Chills	35/37 (94.59%; 81.81%-99.34%)	2/37 (5.41%; 0.66%-18.19%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	2/37 (5.41%; 0.66%-18.19%)
	Feverishness	34/37 (91.89%; 78.09%-98.30%)	2/37 (5.41%; 0.66%-18.19%)	1/37 (2.70%; 0.07%-14.16%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	3/37 (8.11%; 1.70%-21.91%)
	Joint pains	34/37 (91.89%; 78.09%-98.30%)	2/37 (5.41%; 0.66%-18.19%)	1/37 (2.70%; 0.07%-14.16%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	3/37 (8.11%; 1.70%-21.91%)
	Muscle pains	29/37 (78.38%; 61.79%-90.17%)	8/37 (21.62%; 9.83%-38.21%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	8/37 (21.62%; 9.83%-38.21%)
	Fatigue	27/37 (72.97%; 55.88%-86.21%)	9/37 (24.32%; 11.77%-41.20%)	1/37 (2.70%; 0.07%-14.16%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	10/37 (27.03%; 13.79%-44.12%)
	Headache	26/37 (70.27%; 53.02%-84.13%)	9/37 (24.32%; 11.77%-41.20%)	2/37 (5.41%; 0.66%-18.19%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	11/37 (29.73%; 15.87%-46.98%)
	Nausea	36/37 (97.30%; 85.84%-99.93%)	1/37 (2.70%; 0.07%-14.16%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	1/37 (2.70%; 0.07%-14.16%)
	Malaise	31/37 (83.78%; 67.99%-93.81%)	6/37 (16.22%; 6.19%-32.01%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	0/37 (0.00%; 0.00%-9.49%)	6/37 (16.22%; 6.19%-32.01%)
Placebo	Redness	8/8 (100.00%; 63.06%-100.00%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)
	Warmth	8/8 (100.00%; 63.06%-100.00%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)
	Itch	8/8 (100.00%; 63.06%-100.00%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)

Arm	Symptom	Maximum severity					
		None	Mild	Moderate	Severe	Hospitalised	Any
	Pain	7/8 (87.50%; 47.35%-99.68%)	1/8 (12.50%; 0.32%-52.65%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	1/8 (12.50%; 0.32%-52.65%)
	Swelling	8/8 (100.00%; 63.06%-100.00%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)
	Fever ≥38°C	8/8 (100.00%; 63.06%-100.00%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)
	Chills	8/8 (100.00%; 63.06%-100.00%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)
	Feverishness	8/8 (100.00%; 63.06%-100.00%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)
	Joint pains	8/8 (100.00%; 63.06%-100.00%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)
	Muscle pains	8/8 (100.00%; 63.06%-100.00%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)
	Fatigue	6/8 (75.00%; 34.91%-96.81%)	2/8 (25.00%; 3.19%-65.09%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	2/8 (25.00%; 3.19%-65.09%)
	Headache	6/8 (75.00%; 34.91%-96.81%)	2/8 (25.00%; 3.19%-65.09%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	2/8 (25.00%; 3.19%-65.09%)
	Nausea	7/8 (87.50%; 47.35%-99.68%)	1/8 (12.50%; 0.32%-52.65%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	1/8 (12.50%; 0.32%-52.65%)
	Malaise	8/8 (100.00%; 63.06%-100.00%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)

Maximum severity of solicited adverse events during days 0-6 after second vaccination: group 1

Arm	Symptom	Maximum severity					
		None	Mild	Moderate	Severe	Hospitalised	Any
ChAdOx1 MERS	Redness	35/35 (100.00%; 90.00%-100.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)
	Warmth	29/35 (82.86%; 66.35%-93.44%)	6/35 (17.14%; 6.56%-33.65%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	6/35 (17.14%; 6.56%-33.65%)
	Itch	35/35 (100.00%; 90.00%-100.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)
	Pain	18/35 (51.43%; 33.99%-68.62%)	15/35 (42.86%; 26.32%-60.65%)	2/35 (5.71%; 0.70%-19.16%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	17/35 (48.57%; 31.38%-66.01%)
	Swelling	35/35 (100.00%; 90.00%-100.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)
	Fever ≥38°C	35/35 (100.00%; 90.00%-100.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)
	Chills	34/35 (97.14%; 85.08%-99.93%)	0/35 (0.00%; 0.00%-10.00%)	1/35 (2.86%; 0.07%-14.92%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	1/35 (2.86%; 0.07%-14.92%)
	Feverishness	35/35 (100.00%; 90.00%-100.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)
	Joint pains	31/35 (88.57%; 73.26%-96.80%)	3/35 (8.57%; 1.80%-23.06%)	1/35 (2.86%; 0.07%-14.92%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	4/35 (11.43%; 3.20%-26.74%)
	Muscle pains	28/35 (80.00%; 63.06%-91.56%)	6/35 (17.14%; 6.56%-33.65%)	1/35 (2.86%; 0.07%-14.92%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	7/35 (20.00%; 8.44%-36.94%)
	Fatigue	30/35 (85.71%; 69.74%-95.19%)	3/35 (8.57%; 1.80%-23.06%)	2/35 (5.71%; 0.70%-19.16%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	5/35 (14.29%; 4.81%-30.26%)
	Headache	29/35 (82.86%; 66.35%-93.44%)	4/35 (11.43%; 3.20%-26.74%)	2/35 (5.71%; 0.70%-19.16%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	6/35 (17.14%; 6.56%-33.65%)
	Nausea	34/35 (97.14%; 85.08%-99.93%)	1/35 (2.86%; 0.07%-14.92%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	1/35 (2.86%; 0.07%-14.92%)
	Malaise	29/35 (82.86%; 66.35%-93.44%)	4/35 (11.43%; 3.20%-26.74%)	2/35 (5.71%; 0.70%-19.16%)	0/35 (0.00%; 0.00%-10.00%)	0/35 (0.00%; 0.00%-10.00%)	6/35 (17.14%; 6.56%-33.65%)
Placebo	Redness	8/8 (100.00%; 63.06%-100.00%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)
	Warmth	6/8 (75.00%; 34.91%-96.81%)	2/8 (25.00%; 3.19%-65.09%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	2/8 (25.00%; 3.19%-65.09%)
	Itch	8/8 (100.00%; 63.06%-100.00%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)

Arm	Symptom	Maximum severity					
		None	Mild	Moderate	Severe	Hospitalised	Any
	Pain	6/8 (75.00%; 34.91%-96.81%)	2/8 (25.00%; 3.19%-65.09%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	2/8 (25.00%; 3.19%-65.09%)
	Swelling	8/8 (100.00%; 63.06%-100.00%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)
	Fever ≥38°C	8/8 (100.00%; 63.06%-100.00%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)
	Chills	7/8 (87.50%; 47.35%-99.68%)	1/8 (12.50%; 0.32%-52.65%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	1/8 (12.50%; 0.32%-52.65%)
	Feverishness	8/8 (100.00%; 63.06%-100.00%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)
	Joint pains	7/8 (87.50%; 47.35%-99.68%)	1/8 (12.50%; 0.32%-52.65%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	1/8 (12.50%; 0.32%-52.65%)
	Muscle pains	6/8 (75.00%; 34.91%-96.81%)	2/8 (25.00%; 3.19%-65.09%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	2/8 (25.00%; 3.19%-65.09%)
	Fatigue	6/8 (75.00%; 34.91%-96.81%)	2/8 (25.00%; 3.19%-65.09%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	2/8 (25.00%; 3.19%-65.09%)
	Headache	5/8 (62.50%; 24.49%-91.48%)	3/8 (37.50%; 8.52%-75.51%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	3/8 (37.50%; 8.52%-75.51%)
	Nausea	7/8 (87.50%; 47.35%-99.68%)	1/8 (12.50%; 0.32%-52.65%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	1/8 (12.50%; 0.32%-52.65%)
	Malaise	8/8 (100.00%; 63.06%-100.00%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)	0/8 (0.00%; 0.00%-36.94%)

Maximum severity of solicited adverse events during days 0-6 after first vaccination: group 2

Arm	Symptom	Maximum severity					
		None	Mild	Moderate	Severe	Hospitalised	Any
ChAdOx1 MERS	Redness	33/33 (100.00%; 89.42%-100.00%)	0/33 (0.00%; 0.00%-10.58%)	0/33 (0.00%; 0.00%-10.58%)	0/33 (0.00%; 0.00%-10.58%)	0/33 (0.00%; 0.00%-10.58%)	0/33 (0.00%; 0.00%-10.58%)
	Warmth	29/33 (87.88%; 71.80%-96.60%)	4/33 (12.12%; 3.40%-28.20%)	0/33 (0.00%; 0.00%-10.58%)	0/33 (0.00%; 0.00%-10.58%)	0/33 (0.00%; 0.00%-10.58%)	4/33 (12.12%; 3.40%-28.20%)
	Itch	31/33 (93.94%; 79.77%-99.26%)	2/33 (6.06%; 0.74%-20.23%)	0/33 (0.00%; 0.00%-10.58%)	0/33 (0.00%; 0.00%-10.58%)	0/33 (0.00%; 0.00%-10.58%)	2/33 (6.06%; 0.74%-20.23%)
	Pain	19/33 (57.58%; 39.22%-74.52%)	14/33 (42.42%; 25.48%-60.78%)	0/33 (0.00%; 0.00%-10.58%)	0/33 (0.00%; 0.00%-10.58%)	0/33 (0.00%; 0.00%-10.58%)	14/33 (42.42%; 25.48%-60.78%)
	Swelling	33/33 (100.00%; 89.42%-100.00%)	0/33 (0.00%; 0.00%-10.58%)	0/33 (0.00%; 0.00%-10.58%)	0/33 (0.00%; 0.00%-10.58%)	0/33 (0.00%; 0.00%-10.58%)	0/33 (0.00%; 0.00%-10.58%)
	Fever ≥38°C	32/33 (96.97%; 84.24%-99.92%)	1/33 (3.03%; 0.08%-15.76%)	0/33 (0.00%; 0.00%-10.58%)	0/33 (0.00%; 0.00%-10.58%)	0/33 (0.00%; 0.00%-10.58%)	1/33 (3.03%; 0.08%-15.76%)
	Chills	26/33 (78.79%; 61.09%-91.02%)	3/33 (9.09%; 1.92%-24.33%)	3/33 (9.09%; 1.92%-24.33%)	1/33 (3.03%; 0.08%-15.76%)	0/33 (0.00%; 0.00%-10.58%)	7/33 (21.21%; 8.98%-38.91%)
	Feverishness	24/33 (72.73%; 54.48%-86.70%)	6/33 (18.18%; 6.98%-35.46%)	2/33 (6.06%; 0.74%-20.23%)	1/33 (3.03%; 0.08%-15.76%)	0/33 (0.00%; 0.00%-10.58%)	9/33 (27.27%; 13.30%-45.52%)
	Joint pains	26/33 (78.79%; 61.09%-91.02%)	4/33 (12.12%; 3.40%-28.20%)	3/33 (9.09%; 1.92%-24.33%)	0/33 (0.00%; 0.00%-10.58%)	0/33 (0.00%; 0.00%-10.58%)	7/33 (21.21%; 8.98%-38.91%)
	Muscle pains	17/33 (51.52%; 33.54%-69.20%)	13/33 (39.39%; 22.91%-57.86%)	3/33 (9.09%; 1.92%-24.33%)	0/33 (0.00%; 0.00%-10.58%)	0/33 (0.00%; 0.00%-10.58%)	16/33 (48.48%; 30.80%-66.46%)
	Fatigue	17/33 (51.52%; 33.54%-69.20%)	9/33 (27.27%; 13.30%-45.52%)	6/33 (18.18%; 6.98%-35.46%)	1/33 (3.03%; 0.08%-15.76%)	0/33 (0.00%; 0.00%-10.58%)	16/33 (48.48%; 30.80%-66.46%)
	Headache	15/33 (45.45%; 28.11%-63.65%)	13/33 (39.39%; 22.91%-57.86%)	4/33 (12.12%; 3.40%-28.20%)	1/33 (3.03%; 0.08%-15.76%)	0/33 (0.00%; 0.00%-10.58%)	18/33 (54.55%; 36.35%-71.89%)
	Nausea	28/33 (84.85%; 68.10%-94.89%)	3/33 (9.09%; 1.92%-24.33%)	2/33 (6.06%; 0.74%-20.23%)	0/33 (0.00%; 0.00%-10.58%)	0/33 (0.00%; 0.00%-10.58%)	5/33 (15.15%; 5.11%-31.90%)
	Malaise	23/33 (69.70%; 51.29%-84.41%)	4/33 (12.12%; 3.40%-28.20%)	6/33 (18.18%; 6.98%-35.46%)	0/33 (0.00%; 0.00%-10.58%)	0/33 (0.00%; 0.00%-10.58%)	10/33 (30.30%; 15.59%-48.71%)
Placebo	Redness	6/6 (100.00%; 54.07%-100.00%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)
	Warmth	6/6 (100.00%; 54.07%-100.00%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)
	Itch	5/6 (83.33%; 35.88%-99.58%)	1/6 (16.67%; 0.42%-64.12%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	1/6 (16.67%; 0.42%-64.12%)

Arm	Symptom	Maximum severity					
		None	Mild	Moderate	Severe	Hospitalised	Any
	Pain	5/6 (83.33%; 35.88%-99.58%)	1/6 (16.67%; 0.42%-64.12%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	1/6 (16.67%; 0.42%-64.12%)
	Swelling	6/6 (100.00%; 54.07%-100.00%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)
	Fever ≥38°C	6/6 (100.00%; 54.07%-100.00%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)
	Chills	6/6 (100.00%; 54.07%-100.00%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)
	Feverishness	6/6 (100.00%; 54.07%-100.00%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)
	Joint pains	6/6 (100.00%; 54.07%-100.00%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)
	Muscle pains	6/6 (100.00%; 54.07%-100.00%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)
	Fatigue	6/6 (100.00%; 54.07%-100.00%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)
	Headache	5/6 (83.33%; 35.88%-99.58%)	1/6 (16.67%; 0.42%-64.12%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	1/6 (16.67%; 0.42%-64.12%)
	Nausea	6/6 (100.00%; 54.07%-100.00%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)
	Malaise	6/6 (100.00%; 54.07%-100.00%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)

Maximum severity of solicited adverse events during days 0-6 after second vaccination: group 2

Arm	Symptom	Maximum severity					
		None	Mild	Moderate	Severe	Hospitalised	Any
ChAdOx1 MERS	Redness	32/32 (100.00%; 89.11%-100.00%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)
	Warmth	30/32 (93.75%; 79.19%-99.23%)	2/32 (6.25%; 0.77%-20.81%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	2/32 (6.25%; 0.77%-20.81%)
	Itch	30/32 (93.75%; 79.19%-99.23%)	2/32 (6.25%; 0.77%-20.81%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	2/32 (6.25%; 0.77%-20.81%)
	Pain	19/32 (59.38%; 40.64%-76.30%)	13/32 (40.63%; 23.70%-59.36%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	13/32 (40.63%; 23.70%-59.36%)
	Swelling	32/32 (100.00%; 89.11%-100.00%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)
	Fever ≥38°C	32/32 (100.00%; 89.11%-100.00%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)
	Chills	31/32 (96.88%; 83.78%-99.92%)	1/32 (3.13%; 0.08%-16.22%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	1/32 (3.13%; 0.08%-16.22%)
	Feverishness	32/32 (100.00%; 89.11%-100.00%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)
	Joint pains	27/32 (84.38%; 67.21%-94.72%)	4/32 (12.50%; 3.51%-28.99%)	1/32 (3.13%; 0.08%-16.22%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	5/32 (15.63%; 5.28%-32.79%)
	Muscle pains	24/32 (75.00%; 56.60%-88.54%)	8/32 (25.00%; 11.46%-43.40%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	8/32 (25.00%; 11.46%-43.40%)
	Fatigue	22/32 (68.75%; 49.99%-83.88%)	10/32 (31.25%; 16.12%-50.01%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	10/32 (31.25%; 16.12%-50.01%)
	Headache	24/32 (75.00%; 56.60%-88.54%)	7/32 (21.88%; 9.28%-39.97%)	1/32 (3.13%; 0.08%-16.22%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	8/32 (25.00%; 11.46%-43.40%)
	Nausea	29/32 (90.63%; 74.98%-98.02%)	2/32 (6.25%; 0.77%-20.81%)	1/32 (3.13%; 0.08%-16.22%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	3/32 (9.38%; 1.98%-25.02%)
	Malaise	27/32 (84.38%; 67.21%-94.72%)	5/32 (15.63%; 5.28%-32.79%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	0/32 (0.00%; 0.00%-10.89%)	5/32 (15.63%; 5.28%-32.79%)
Placebo	Redness	6/6 (100.00%; 54.07%-100.00%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)
	Warmth	6/6 (100.00%; 54.07%-100.00%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)
	Itch	6/6 (100.00%; 54.07%-100.00%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)

Arm	Symptom	Maximum severity					
		None	Mild	Moderate	Severe	Hospitalised	Any
	Pain	5/6 (83.33%; 35.88%-99.58%)	1/6 (16.67%; 0.42%-64.12%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	1/6 (16.67%; 0.42%-64.12%)
	Swelling	6/6 (100.00%; 54.07%-100.00%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)
	Fever ≥38°C	6/6 (100.00%; 54.07%-100.00%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)
	Chills	5/6 (83.33%; 35.88%-99.58%)	1/6 (16.67%; 0.42%-64.12%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	1/6 (16.67%; 0.42%-64.12%)
	Feverishness	3/6 (50.00%; 11.81%-88.19%)	3/6 (50.00%; 11.81%-88.19%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	3/6 (50.00%; 11.81%-88.19%)
	Joint pains	4/6 (66.67%; 22.28%-95.67%)	2/6 (33.33%; 4.33%-77.72%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	2/6 (33.33%; 4.33%-77.72%)
	Muscle pains	4/6 (66.67%; 22.28%-95.67%)	2/6 (33.33%; 4.33%-77.72%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	2/6 (33.33%; 4.33%-77.72%)
	Fatigue	4/6 (66.67%; 22.28%-95.67%)	1/6 (16.67%; 0.42%-64.12%)	1/6 (16.67%; 0.42%-64.12%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	2/6 (33.33%; 4.33%-77.72%)
	Headache	4/6 (66.67%; 22.28%-95.67%)	2/6 (33.33%; 4.33%-77.72%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	2/6 (33.33%; 4.33%-77.72%)
	Nausea	4/6 (66.67%; 22.28%-95.67%)	2/6 (33.33%; 4.33%-77.72%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	2/6 (33.33%; 4.33%-77.72%)
	Malaise	4/6 (66.67%; 22.28%-95.67%)	2/6 (33.33%; 4.33%-77.72%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	0/6 (0.00%; 0.00%-45.93%)	2/6 (33.33%; 4.33%-77.72%)

3.2 Occurrence of unsolicited adverse events (AEs)

Outcome measure	Evaluation Timepoints*
c) Occurrence of unsolicited adverse events (AEs)	Within 28 days of each vaccination

Summary of unsolicited AEs (excluding SAEs)

Group	Arm	Participants with ≥ 1 AE	AEs	Causality				AEs of severity grade ≥3	AESI
				No relationship	Possible	Probable	Definite		
1	ChAdOx1 MERS (n=37)	23 (62%)	61	42/61 (69%)	17/61 (28%)	1/61 (2%)	1/61 (2%)	9/61 (15%)	0
	Placebo (n=8)	8 (100%)	17	13/17 (76%)	4/17 (24%)	0/17 (0%)	0/17 (0%)	3/17 (18%)	0
2	ChAdOx1 MERS (n=33)	22 (67%)	49	34/49 (69%)	15/49 (31%)	0/49 (0%)	0/49 (0%)	7/49 (14%)	0
	Placebo (n=6)	6 (100%)	8	5/8 (63%)	3/8 (38%)	0/8 (0%)	0/8 (0%)	0/8 (0%)	0
All (n=84)		59 (70%)	135	94/135 (70%)	39/135 (29%)	1/135 (1%)	1/135 (1%)	19/135 (14%)	0

Note that the number of AE entries can be higher than the number of participants reporting AEs, where some participants have reported multiple AEs.

Summary of all unsolicited AEs (including any SAEs and AESIs) by MedDRA System Organ Class and Preferred Term

System Organ Class	Preferred Term	Group 1		Group 2		All
		ChAdOx1 MERS	Placebo	ChAdOx1 MERS	Placebo	
All events		61	18	52	8	139
Blood and lymphatic system disorders	*All*	*3 (4.9%)*	*0 (0%)*	*1 (1.9%)*	*0 (0%)*	*4 (2.9%)*
	Anaemia	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Lymphadenopathy	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
	Neutropenia	2 (3.3%)	0 (0%)	0 (0%)	0 (0%)	2 (1.4%)
Cardiac disorders	*All*	*1 (1.6%)*	*0 (0%)*	*0 (0%)*	*0 (0%)*	*1 (0.7%)*
	Bradycardia	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
Ear and labyrinth disorders	*All*	*0 (0%)*	*0 (0%)*	*1 (1.9%)*	*0 (0%)*	*1 (0.7%)*
	Labyrinthitis	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
Eye disorders	*All*	*0 (0%)*	*0 (0%)*	*1 (1.9%)*	*0 (0%)*	*1 (0.7%)*
	Dry eye	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
Gastrointestinal disorders	*All*	*6 (9.8%)*	*2 (11.1%)*	*6 (11.5%)*	*0 (0%)*	*14 (10.1%)*
	Abdominal discomfort	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Abdominal pain	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
	Abdominal pain upper	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Gastritis	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Haemorrhoids	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
	Oral candidiasis	0 (0%)	1 (5.6%)	0 (0%)	0 (0%)	1 (0.7%)
	Oral herpes	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
	Taste disorder	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Toothache	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
	Vomiting	2 (3.3%)	1 (5.6%)	2 (3.8%)	0 (0%)	5 (3.6%)
General disorders and administration site conditions	*All*	*1 (1.6%)*	*0 (0%)*	*1 (1.9%)*	*0 (0%)*	*2 (1.4%)*
	Drowning	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Influenza like illness	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
Hepatobiliary disorders	*All*	*0 (0%)*	*1 (5.6%)*	*0 (0%)*	*0 (0%)*	*1 (0.7%)*
	Cholelithiasis	0 (0%)	1 (5.6%)	0 (0%)	0 (0%)	1 (0.7%)
Infections and infestations	*All*	*14 (23.0%)*	*5 (27.8%)*	*9 (17.3%)*	*1 (12.5%)*	*29 (20.9%)*
	Eye infection	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
	Gastroenteritis	0 (0%)	1 (5.6%)	1 (1.9%)	0 (0%)	2 (1.4%)
	Helicobacter infection	0 (0%)	1 (5.6%)	0 (0%)	0 (0%)	1 (0.7%)
	Hordeolum	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Lower respiratory tract infection	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Nasopharyngitis	4 (6.6%)	2 (11.1%)	2 (3.8%)	0 (0%)	8 (5.8%)
	Oral herpes	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Otitis externa	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Rhinitis	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
	Suspected COVID-19	0 (0%)	0 (0%)	0 (0%)	1 (12.5%)	1 (0.7%)
	Tooth infection	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
	Upper respiratory tract infection	7 (11.5%)	0 (0%)	2 (3.8%)	0 (0%)	9 (6.5%)
	Urinary tract infection	0 (0%)	1 (5.6%)	0 (0%)	0 (0%)	1 (0.7%)
Injury, poisoning and procedural complications	*All*	*1 (1.6%)*	*1 (5.6%)*	*4 (7.7%)*	*0 (0%)*	*6 (4.3%)*
	Clavicle fracture	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Foot fracture	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
	Joint dislocation	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Ligament sprain	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Muscle strain	0 (0%)	1 (5.6%)	0 (0%)	0 (0%)	1 (0.7%)
	Post procedural complication	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)

System Organ Class	Preferred Term	Group 1		Group 2		All
		ChAdOx1 MERS	Placebo	ChAdOx1 MERS	Placebo	
Investigations	*All*	*20 (32.8%)*	*3 (16.7%)*	*6 (11.5%)*	*2 (25.0%)*	*31 (22.3%)*
	Alanine aminotransferase increased	1 (1.6%)	0 (0%)	1 (1.9%)	0 (0%)	2 (1.4%)
	Blood bilirubin increased	0 (0%)	0 (0%)	0 (0%)	1 (12.5%)	1 (0.7%)
	Blood potassium increased	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
	Blood pressure diastolic increased	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
	Blood pressure increased	14 (23.0%)	1 (5.6%)	2 (3.8%)	1 (12.5%)	18 (12.9%)
	Blood pressure systolic increased	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
	Blood sodium decreased	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
	Blood urea increased	0 (0%)	0 (0%)	2 (3.8%)	0 (0%)	2 (1.4%)
	Glomerular filtration rate decreased	0 (0%)	1 (5.6%)	0 (0%)	0 (0%)	1 (0.7%)
	Heart rate increased	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
	Neutrophil count decreased	0 (0%)	1 (5.6%)	1 (1.9%)	0 (0%)	2 (1.4%)
Metabolism and nutrition disorders	*All*	*0 (0%)*	*0 (0%)*	*1 (1.9%)*	*1 (12.5%)*	*2 (1.4%)*
	Hypoglycaemia	0 (0%)	0 (0%)	0 (0%)	1 (12.5%)	1 (0.7%)
	Iron deficiency	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
Musculoskeletal and connective tissue disorders	*All*	*2 (3.3%)*	*2 (11.1%)*	*9 (17.3%)*	*2 (25.0%)*	*15 (10.8%)*
	Arthralgia	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
	Arthritis	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
	Back pain	0 (0%)	2 (11.1%)	2 (3.8%)	2 (25.0%)	6 (4.3%)
	Jaw clicking	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Muscle spasms	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Neck pain	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Pain in extremity	0 (0%)	0 (0%)	2 (3.8%)	0 (0%)	2 (1.4%)
	Periarthritis	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Synovitis	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	*All*	*1 (1.6%)*	*0 (0%)*	*1 (1.9%)*	*0 (0%)*	*2 (1.4%)*
	Basal cell carcinoma	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Infected dermal cyst	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
Nervous system disorders Dementia with Lewy bodies	*All*	*2 (3.3%)*	*0 (0%)*	*2 (3.8%)*	*0 (0%)*	*4 (2.9%)*
	Dementia with Lewy bodies	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Headache	1 (1.6%)	0 (0%)	1 (1.9%)	0 (0%)	2 (1.4%)
	Paraesthesia	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
Renal and urinary disorders	*All*	*0 (0%)*	*0 (0%)*	*1 (1.9%)*	*0 (0%)*	*1 (0.7%)*
	Haematuria	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
Reproductive system and breast disorders	*All*	*2 (3.3%)*	*2 (11.1%)*	*1 (1.9%)*	*0 (0%)*	*5 (3.6%)*
	Benign breast neoplasm	0 (0%)	1 (5.6%)	0 (0%)	0 (0%)	1 (0.7%)
	Benign prostatic hyperplasia	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Menstrual disorder	2 (3.3%)	0 (0%)	0 (0%)	0 (0%)	2 (1.4%)
	Prostatitis	0 (0%)	1 (5.6%)	0 (0%)	0 (0%)	1 (0.7%)
Respiratory, thoracic and mediastinal disorders	*All*	*6 (9.8%)*	*0 (0%)*	*3 (5.8%)*	*1 (12.5%)*	*10 (7.2%)*
	Cough	1 (1.6%)	0 (0%)	2 (3.8%)	0 (0%)	3 (2.2%)
	Nasal congestion	1 (1.6%)	0 (0%)	1 (1.9%)	0 (0%)	2 (1.4%)
	Nasopharyngitis	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)

System Organ Class	Preferred Term	Group 1		Group 2		All
		ChAdOx1 MERS	Placebo	ChAdOx1 MERS	Placebo	
	Oropharyngeal pain	3 (4.9%)	0 (0%)	0 (0%)	1 (12.5%)	4 (2.9%)
Skin and subcutaneous tissue disorders	*All*	*1 (1.6%)*	*0 (0%)*	*3 (5.8%)*	*1 (12.5%)*	*5 (3.6%)*
	Ingrowing nail	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Intertrigo	0 (0%)	0 (0%)	0 (0%)	1 (12.5%)	1 (0.7%)
	Pruritus	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Rash	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
	Skin ulcer	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
Surgical and medical procedures	*All*	*0 (0%)*	*2 (11.1%)*	*0 (0%)*	*0 (0%)*	*2 (1.4%)*
	Thyroid nodule removal	0 (0%)	1 (5.6%)	0 (0%)	0 (0%)	1 (0.7%)
	Tooth extraction	0 (0%)	1 (5.6%)	0 (0%)	0 (0%)	1 (0.7%)
Vascular disorders	*All*	*1 (1.6%)*	*0 (0%)*	*2 (3.8%)*	*0 (0%)*	*3 (2.2%)*
	Flushing	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)
	Hypertension	1 (1.6%)	0 (0%)	0 (0%)	0 (0%)	1 (0.7%)
	Hypotension	0 (0%)	0 (0%)	1 (1.9%)	0 (0%)	1 (0.7%)

Summary of participants with unsolicited AEs (including SAEs and AESIs) by MedDRA System Organ Class and Preferred Term

System Organ Class	Preferred Term	Group 1		Group 2		All (n=84)
		ChAdOx1 MERS (n=37)	Placebo (n=8)	ChAdOx1 MERS (n=33)	Placebo (n=6)	
Any event		23 (62.2%)	8 (100.0%)	24 (72.7%)	6 (100.0%)	61 (72.6%)
Blood and lymphatic system disorders	*All*	*3 (8.1%)*	*0 (0%)*	*1 (3.0%)*	*0 (0%)*	*4 (4.8%)*
	Anaemia	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Lymphadenopathy	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
	Neutropenia	2 (5.4%)	0 (0%)	0 (0%)	0 (0%)	2 (2.4%)
Cardiac disorders	*All*	*1 (2.7%)*	*0 (0%)*	*0 (0%)*	*0 (0%)*	*1 (1.2%)*
	Bradycardia	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
Ear and labyrinth disorders	*All*	*0 (0%)*	*0 (0%)*	*1 (3.0%)*	*0 (0%)*	*1 (1.2%)*
	Labyrinthitis	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
Eye disorders	*All*	*0 (0%)*	*0 (0%)*	*1 (3.0%)*	*0 (0%)*	*1 (1.2%)*
	Dry eye	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
Gastrointestinal disorders	*All*	*5 (13.5%)*	*2 (25.0%)*	*5 (15.2%)*	*0 (0%)*	*12 (14.3%)*
	Abdominal discomfort	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Abdominal pain	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
	Abdominal pain upper	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Gastritis	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Haemorrhoids	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
	Oral candidiasis	0 (0%)	1 (12.5%)	0 (0%)	0 (0%)	1 (1.2%)
	Oral herpes	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
	Taste disorder	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Toothache	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
	Vomiting	2 (5.4%)	1 (12.5%)	2 (6.1%)	0 (0%)	4 (4.8%)
General disorders and administration site conditions	*All*	*1 (2.7%)*	*0 (0%)*	*1 (3.0%)*	*0 (0%)*	*2 (2.4%)*
	Drowning	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Influenza like illness	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
Hepatobiliary disorders	*All*	*0 (0%)*	*1 (12.5%)*	*0 (0%)*	*0 (0%)*	*1 (1.2%)*
	Cholelithiasis	0 (0%)	1 (12.5%)	0 (0%)	0 (0%)	1 (1.2%)
Infections and infestations	*All*	*11 (29.7%)*	*5 (62.5%)*	*9 (27.3%)*	*1 (16.7%)*	*26 (31.0%)*
	Eye infection	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
	Gastroenteritis	0 (0%)	1 (12.5%)	1 (3.0%)	0 (0%)	2 (2.4%)
	Helicobacter infection	0 (0%)	1 (12.5%)	0 (0%)	0 (0%)	1 (1.2%)
	Hordeolum	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Lower respiratory tract infection	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Nasopharyngitis	4 (10.8%)	2 (25.0%)	2 (6.1%)	0 (0%)	8 (9.5%)
	Oral herpes	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Otitis externa	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Rhinitis	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
	Suspected COVID-19	0 (0%)	0 (0%)	0 (0%)	1 (16.7%)	1 (1.2%)
	Tooth infection	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
	Upper respiratory tract infection	7 (18.9%)	0 (0%)	2 (6.1%)	0 (0%)	8 (9.5%)
	Urinary tract infection	0 (0%)	1 (12.5%)	0 (0%)	0 (0%)	1 (1.2%)
Injury, poisoning and procedural complications	*All*	*1 (2.7%)*	*1 (12.5%)*	*4 (12.1%)*	*0 (0%)*	*6 (7.1%)*
	Clavicle fracture	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Foot fracture	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
	Joint dislocation	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Ligament sprain	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Muscle strain	0 (0%)	1 (12.5%)	0 (0%)	0 (0%)	1 (1.2%)
	Post procedural complication	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)

System Organ Class	Preferred Term	Group 1		Group 2		All (n=84)
		ChAdOx1 MERS (n=37)	Placebo (n=8)	ChAdOx1 MERS (n=33)	Placebo (n=6)	
Investigations	*All*	*14 (37.8%)*	*2 (25.0%)*	*5 (15.2%)*	*2 (33.3%)*	*23 (27.4%)*
	Alanine aminotransferase increased	1 (2.7%)	0 (0%)	1 (3.0%)	0 (0%)	2 (2.4%)
	Blood bilirubin increased	0 (0%)	0 (0%)	0 (0%)	1 (16.7%)	1 (1.2%)
	Blood potassium increased	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
	Blood pressure diastolic increased	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
	Blood pressure increased	14 (37.8%)	1 (12.5%)	2 (6.1%)	1 (16.7%)	15 (17.9%)
	Blood pressure systolic increased	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
	Blood sodium decreased	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
	Blood urea increased	0 (0%)	0 (0%)	2 (6.1%)	0 (0%)	1 (1.2%)
	Glomerular filtration rate decreased	0 (0%)	1 (12.5%)	0 (0%)	0 (0%)	1 (1.2%)
	Heart rate increased	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
	Neutrophil count decreased	0 (0%)	1 (12.5%)	1 (3.0%)	0 (0%)	2 (2.4%)
Metabolism and nutrition disorders	*All*	*0 (0%)*	*0 (0%)*	*1 (3.0%)*	*1 (16.7%)*	*2 (2.4%)*
	Hypoglycaemia	0 (0%)	0 (0%)	0 (0%)	1 (16.7%)	1 (1.2%)
	Iron deficiency	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
Musculoskeletal and connective tissue disorders	*All*	*2 (5.4%)*	*2 (25.0%)*	*9 (27.3%)*	*2 (33.3%)*	*15 (17.9%)*
	Arthralgia	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
	Arthritis	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
	Back pain	0 (0%)	2 (25.0%)	2 (6.1%)	2 (33.3%)	6 (7.1%)
	Jaw clicking	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Muscle spasms	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Neck pain	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Pain in extremity	0 (0%)	0 (0%)	2 (6.1%)	0 (0%)	2 (2.4%)
	Periarthritis	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Synovitis	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	*All*	*1 (2.7%)*	*0 (0%)*	*1 (3.0%)*	*0 (0%)*	*2 (2.4%)*
	Basal cell carcinoma	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Infected dermal cyst	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
Nervous system disorders	*All*	*2 (5.4%)*	*0 (0%)*	*2 (6.1%)*	*0 (0%)*	*4 (4.8%)*
	Dementia with Lewy bodies	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Headache	1 (2.7%)	0 (0%)	1 (3.0%)	0 (0%)	2 (2.4%)
	Paraesthesia	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
Renal and urinary disorders	*All*	*0 (0%)*	*0 (0%)*	*1 (3.0%)*	*0 (0%)*	*1 (1.2%)*
	Haematuria	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
Reproductive system and breast disorders	*All*	*1 (2.7%)*	*2 (25.0%)*	*1 (3.0%)*	*0 (0%)*	*4 (4.8%)*
	Benign breast neoplasm	0 (0%)	1 (12.5%)	0 (0%)	0 (0%)	1 (1.2%)
	Benign prostatic hyperplasia	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Menstrual disorder	2 (5.4%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
	Prostatitis	0 (0%)	1 (12.5%)	0 (0%)	0 (0%)	1 (1.2%)
Respiratory, thoracic and mediastinal disorders	*All*	*6 (16.2%)*	*0 (0%)*	*3 (9.1%)*	*1 (16.7%)*	*10 (11.9%)*
	Cough	1 (2.7%)	0 (0%)	2 (6.1%)	0 (0%)	3 (3.6%)
	Nasal congestion	1 (2.7%)	0 (0%)	1 (3.0%)	0 (0%)	2 (2.4%)

System Organ Class	Preferred Term	Group 1		Group 2		All (n=84)
		ChAdOx1 MERS (n=37)	Placebo (n=8)	ChAdOx1 MERS (n=33)	Placebo (n=6)	
	Nasopharyngitis	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
	Oropharyngeal pain	3 (8.1%)	0 (0%)	0 (0%)	1 (16.7%)	4 (4.8%)
Skin and subcutaneous tissue disorders	*All*	*1 (2.7%)*	*0 (0%)*	*3 (9.1%)*	*1 (16.7%)*	*5 (6.0%)*
	Ingrowing nail	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Intertrigo	0 (0%)	0 (0%)	0 (0%)	1 (16.7%)	1 (1.2%)
	Pruritus	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Rash	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
	Skin ulcer	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
Surgical and medical procedures	*All*	*0 (0%)*	*2 (25.0%)*	*0 (0%)*	*0 (0%)*	*2 (2.4%)*
	Thyroid nodule removal	0 (0%)	1 (12.5%)	0 (0%)	0 (0%)	1 (1.2%)
	Tooth extraction	0 (0%)	1 (12.5%)	0 (0%)	0 (0%)	1 (1.2%)
Vascular disorders	*All*	*1 (2.7%)*	*0 (0%)*	*2 (6.1%)*	*0 (0%)*	*3 (3.6%)*
	Flushing	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)
	Hypertension	1 (2.7%)	0 (0%)	0 (0%)	0 (0%)	1 (1.2%)
	Hypotension	0 (0%)	0 (0%)	1 (3.0%)	0 (0%)	1 (1.2%)

Note that numbers of participants within the Preferred Term (PT) categories can exceed those in the corresponding System Organ Class (SOC) category, where participants have multiple events with different PTs under the same SOC.

3.3 Change from baseline for safety laboratory measures

Outcome measure	Evaluation Timepoints*
d) Change from baseline for safety laboratory measures	Within 28 days of each vaccination

Biochemistry results after first vaccination

Group	Arm	Diagnostic test	Severity	Day 0	Day 14	Day 28
1	ChAdOx1 MERS	Sodium inc.	Grade 0	36 (100.0%)	37 (100.0%)	37 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Sodium dec.	Grade 0	35 (97.2%)	37 (100.0%)	37 (100.0%)
			Grade 1	1 (2.8%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Potassium inc.	Grade 0	36 (100.0%)	37 (100.0%)	37 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Potassium dec.	Grade 0	36 (100.0%)	37 (100.0%)	37 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Urea	Grade 0	35 (97.2%)	37 (100.0%)	37 (100.0%)
			Grade 1	1 (2.8%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Creatinine	Grade 0	35 (97.2%)	36 (97.3%)	36 (97.3%)
			Grade 1	1 (2.8%)	1 (2.7%)	1 (2.7%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Alt	Grade 0	35 (97.2%)	37 (100.0%)	37 (100.0%)
			Grade 1	1 (2.8%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		ALP	Grade 0	36 (100.0%)	37 (100.0%)	37 (100.0%)

Group	Arm	Diagnostic test	Severity	Day 0	Day 14	Day 28
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Bilirubin	Grade 0	34 (94.4%)	36 (97.3%)	35 (94.6%)
			Grade 1	2 (5.6%)	1 (2.7%)	2 (5.4%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Albumin	Grade 0	36 (100.0%)	37 (100.0%)	37 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
	Placebo	Sodium inc.	Grade 0	8 (100.0%)	8 (100.0%)	7 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Sodium dec.	Grade 0	8 (100.0%)	8 (100.0%)	7 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Potassium inc.	Grade 0	8 (100.0%)	8 (100.0%)	7 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Potassium dec.	Grade 0	8 (100.0%)	8 (100.0%)	7 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Urea	Grade 0	8 (100.0%)	8 (100.0%)	7 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)

Group	Arm	Diagnostic test	Severity	Day 0	Day 14	Day 28
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Creatinine	Grade 0	8 (100.0%)	7 (87.5%)	7 (100.0%)
			Grade 1	0 (0.0%)	1 (12.5%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Alt	Grade 0	8 (100.0%)	8 (100.0%)	7 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		ALP	Grade 0	8 (100.0%)	8 (100.0%)	7 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Bilirubin	Grade 0	8 (100.0%)	8 (100.0%)	7 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Albumin	Grade 0	8 (100.0%)	8 (100.0%)	7 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	ChAdOx1 MERS	Sodium inc.	Grade 0	32 (100.0%)	33 (100.0%)	32 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Sodium dec.	Grade 0	32 (100.0%)	33 (100.0%)	32 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)

Group	Arm	Diagnostic test	Severity	Day 0	Day 14	Day 28
		Potassium inc.	Grade 0	32 (100.0%)	33 (100.0%)	32 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Potassium dec.	Grade 0	32 (100.0%)	33 (100.0%)	32 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Urea	Grade 0	32 (100.0%)	32 (97.0%)	32 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	1 (3.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Creatinine	Grade 0	32 (100.0%)	33 (100.0%)	32 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Alt	Grade 0	30 (93.8%)	32 (97.0%)	30 (93.8%)
			Grade 1	2 (6.2%)	1 (3.0%)	2 (6.2%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		ALP	Grade 0	32 (100.0%)	33 (100.0%)	32 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Bilirubin	Grade 0	32 (100.0%)	33 (100.0%)	32 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Albumin	Grade 0	32 (100.0%)	33 (100.0%)	32 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)

Group	Arm	Diagnostic test	Severity	Day 0	Day 14	Day 28
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
	Placebo	Sodium inc.	Grade 0	6 (100.0%)	6 (100.0%)	6 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Sodium dec.	Grade 0	6 (100.0%)	6 (100.0%)	6 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Potassium inc.	Grade 0	6 (100.0%)	6 (100.0%)	6 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Potassium dec.	Grade 0	6 (100.0%)	6 (100.0%)	6 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Urea	Grade 0	5 (83.3%)	6 (100.0%)	6 (100.0%)
			Grade 1	1 (16.7%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Creatinine	Grade 0	5 (83.3%)	5 (83.3%)	5 (83.3%)
			Grade 1	1 (16.7%)	1 (16.7%)	1 (16.7%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Alt	Grade 0	5 (83.3%)	5 (83.3%)	6 (100.0%)
			Grade 1	1 (16.7%)	1 (16.7%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)

Group	Arm	Diagnostic test	Severity	Day 0	Day 14	Day 28
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		ALP	Grade 0	6 (100.0%)	6 (100.0%)	6 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Bilirubin	Grade 0	5 (83.3%)	5 (83.3%)	5 (83.3%)
			Grade 1	1 (16.7%)	1 (16.7%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	1 (16.7%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Albumin	Grade 0	6 (100.0%)	6 (100.0%)	6 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)

Biochemistry results after second vaccination

Group	Arm	Diagnostic test	Severity	Day 0	Day 14	Day 28
1	ChAdOx1 MERS	Sodium inc.	Grade 0	35 (100.0%)	36 (100.0%)	33 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Sodium dec.	Grade 0	34 (97.1%)	36 (100.0%)	33 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	1 (2.9%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Potassium inc.	Grade 0	33 (100.0%)	35 (97.2%)	33 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	1 (2.8%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Potassium dec.	Grade 0	33 (100.0%)	36 (100.0%)	33 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Urea	Grade 0	35 (100.0%)	36 (100.0%)	32 (97.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	1 (3.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Creatinine	Grade 0	34 (97.1%)	35 (97.2%)	32 (97.0%)
			Grade 1	1 (2.9%)	1 (2.8%)	1 (3.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Alt	Grade 0	33 (100.0%)	33 (91.7%)	31 (93.9%)
			Grade 1	0 (0.0%)	3 (8.3%)	2 (6.1%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		ALP	Grade 0	35 (100.0%)	36 (100.0%)	33 (100.0%)

Group	Arm	Diagnostic test	Severity	Day 0	Day 14	Day 28
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Bilirubin	Grade 0	31 (93.9%)	34 (94.4%)	31 (93.9%)
			Grade 1	2 (6.1%)	2 (5.6%)	2 (6.1%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Albumin	Grade 0	35 (100.0%)	36 (100.0%)	33 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
	Placebo	Sodium inc.	Grade 0	8 (100.0%)	8 (100.0%)	8 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Sodium dec.	Grade 0	8 (100.0%)	8 (100.0%)	8 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Potassium inc.	Grade 0	8 (100.0%)	8 (100.0%)	8 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Potassium dec.	Grade 0	8 (100.0%)	8 (100.0%)	8 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Urea	Grade 0	8 (100.0%)	8 (100.0%)	8 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)

Group	Arm	Diagnostic test	Severity	Day 0	Day 14	Day 28
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Creatinine	Grade 0	7 (87.5%)	7 (87.5%)	7 (87.5%)
			Grade 1	1 (12.5%)	1 (12.5%)	1 (12.5%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Alt	Grade 0	8 (100.0%)	8 (100.0%)	8 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		ALP	Grade 0	8 (100.0%)	8 (100.0%)	8 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Bilirubin	Grade 0	8 (100.0%)	8 (100.0%)	8 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Albumin	Grade 0	8 (100.0%)	8 (100.0%)	8 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	ChAdOx1 MERS	Sodium inc.	Grade 0	32 (100.0%)	32 (100.0%)	30 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Sodium dec.	Grade 0	32 (100.0%)	32 (100.0%)	30 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)

Group	Arm	Diagnostic test	Severity	Day 0	Day 14	Day 28
		Potassium inc.	Grade 0	32 (100.0%)	32 (100.0%)	30 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Potassium dec.	Grade 0	32 (100.0%)	32 (100.0%)	30 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Urea	Grade 0	30 (93.8%)	31 (96.9%)	29 (96.7%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	2 (6.2%)	1 (3.1%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	1 (3.3%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Creatinine	Grade 0	32 (100.0%)	32 (100.0%)	30 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Alt	Grade 0	31 (96.9%)	31 (96.9%)	29 (96.7%)
			Grade 1	1 (3.1%)	1 (3.1%)	1 (3.3%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		ALP	Grade 0	32 (100.0%)	32 (100.0%)	30 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Bilirubin	Grade 0	32 (100.0%)	32 (100.0%)	30 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Albumin	Grade 0	32 (100.0%)	32 (100.0%)	30 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)

Group	Arm	Diagnostic test	Severity	Day 0	Day 14	Day 28
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
	Placebo	Sodium inc.	Grade 0	6 (100.0%)	6 (100.0%)	5 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Sodium dec.	Grade 0	6 (100.0%)	6 (100.0%)	5 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Potassium inc.	Grade 0	6 (100.0%)	6 (100.0%)	5 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Potassium dec.	Grade 0	6 (100.0%)	6 (100.0%)	5 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Urea	Grade 0	6 (100.0%)	6 (100.0%)	5 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Creatinine	Grade 0	6 (100.0%)	5 (83.3%)	4 (80.0%)
			Grade 1	0 (0.0%)	1 (16.7%)	1 (20.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Alt	Grade 0	5 (83.3%)	6 (100.0%)	5 (100.0%)
			Grade 1	1 (16.7%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)

Group	Arm	Diagnostic test	Severity	Day 0	Day 14	Day 28
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		ALP	Grade 0	6 (100.0%)	6 (100.0%)	5 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Bilirubin	Grade 0	5 (83.3%)	5 (83.3%)	5 (100.0%)
			Grade 1	0 (0.0%)	1 (16.7%)	0 (0.0%)
			Grade 2	1 (16.7%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Albumin	Grade 0	6 (100.0%)	6 (100.0%)	5 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)

Haematology results after first vaccination

Group	Arm	Diagnostic test	Severity	Day 0	Day 14	Day 28
1	ChAdOx1 MERS	Hb dec.	Grade 0	37 (100.0%)	36 (97.3%)	36 (97.3%)
			Grade 1	0 (0.0%)	1 (2.7%)	1 (2.7%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		WBC inc.	Grade 0	37 (100.0%)	37 (100.0%)	37 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		WBC dec.	Grade 0	37 (100.0%)	37 (100.0%)	37 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Platelets dec.	Grade 0	37 (100.0%)	37 (100.0%)	37 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Neutrophils dec.	Grade 0	36 (97.3%)	35 (94.6%)	35 (94.6%)
			Grade 1	1 (2.7%)	2 (5.4%)	2 (5.4%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Lymphocytes dec.	Grade 0	35 (94.6%)	35 (94.6%)	36 (97.3%)
			Grade 1	2 (5.4%)	2 (5.4%)	1 (2.7%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Eosinophils inc.	Grade 0	37 (100.0%)	37 (100.0%)	37 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
	Placebo	Hb dec.	Grade 0	8 (100.0%)	8 (100.0%)	7 (100.0%)

Group	Arm	Diagnostic test	Severity	Day 0	Day 14	Day 28
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		WBC inc.	Grade 0	8 (100.0%)	8 (100.0%)	7 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		WBC dec.	Grade 0	7 (87.5%)	7 (87.5%)	7 (100.0%)
			Grade 1	1 (12.5%)	1 (12.5%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Platelets dec.	Grade 0	8 (100.0%)	8 (100.0%)	7 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Neutrophils dec.	Grade 0	7 (87.5%)	7 (87.5%)	7 (100.0%)
			Grade 1	1 (12.5%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	1 (12.5%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Lymphocytes dec.	Grade 0	7 (87.5%)	7 (87.5%)	6 (85.7%)
			Grade 1	1 (12.5%)	1 (12.5%)	1 (14.3%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Eosinophils inc.	Grade 0	8 (100.0%)	8 (100.0%)	7 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	ChAdOx1 MERS	Hb dec.	Grade 0	32 (97.0%)	29 (87.9%)	30 (93.8%)
			Grade 1	1 (3.0%)	4 (12.1%)	2 (6.2%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)

Group	Arm	Diagnostic test	Severity	Day 0	Day 14	Day 28
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		WBC inc.	Grade 0	33 (100.0%)	32 (97.0%)	32 (100.0%)
			Grade 1	0 (0.0%)	1 (3.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		WBC dec.	Grade 0	31 (93.9%)	32 (97.0%)	31 (96.9%)
			Grade 1	2 (6.1%)	1 (3.0%)	1 (3.1%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Platelets dec.	Grade 0	33 (100.0%)	33 (100.0%)	32 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Neutrophils dec.	Grade 0	31 (93.9%)	30 (90.9%)	30 (93.8%)
			Grade 1	2 (6.1%)	3 (9.1%)	2 (6.2%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Lymphocytes dec.	Grade 0	31 (93.9%)	31 (93.9%)	30 (93.8%)
			Grade 1	1 (3.0%)	2 (6.1%)	2 (6.2%)
			Grade 2	1 (3.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Eosinophils inc.	Grade 0	33 (100.0%)	32 (97.0%)	32 (100.0%)
			Grade 1	0 (0.0%)	1 (3.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
	Placebo	Hb dec.	Grade 0	6 (100.0%)	6 (100.0%)	6 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)

Group	Arm	Diagnostic test	Severity	Day 0	Day 14	Day 28
		WBC inc.	Grade 0	6 (100.0%)	6 (100.0%)	6 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		WBC dec.	Grade 0	6 (100.0%)	6 (100.0%)	6 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Platelets dec.	Grade 0	6 (100.0%)	6 (100.0%)	6 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Neutrophils dec.	Grade 0	6 (100.0%)	5 (83.3%)	5 (83.3%)
			Grade 1	0 (0.0%)	1 (16.7%)	1 (16.7%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Lymphocytes dec.	Grade 0	6 (100.0%)	6 (100.0%)	6 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Eosinophils inc.	Grade 0	6 (100.0%)	6 (100.0%)	6 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)

Haematology results after second vaccination

Group	Arm	Diagnostic test	Severity	Day 0	Day 14	Day 28
1	ChAdOx1 MERS	Hb dec.	Grade 0	34 (97.1%)	33 (91.7%)	31 (93.9%)
			Grade 1	1 (2.9%)	3 (8.3%)	2 (6.1%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		WBC inc.	Grade 0	35 (100.0%)	36 (100.0%)	33 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		WBC dec.	Grade 0	35 (100.0%)	36 (100.0%)	32 (97.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	1 (3.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Platelets dec.	Grade 0	35 (100.0%)	36 (100.0%)	33 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Neutrophils dec.	Grade 0	32 (91.4%)	33 (91.7%)	31 (93.9%)
			Grade 1	3 (8.6%)	3 (8.3%)	1 (3.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	1 (3.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Lymphocytes dec.	Grade 0	32 (91.4%)	36 (100.0%)	31 (93.9%)
			Grade 1	3 (8.6%)	0 (0.0%)	2 (6.1%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Eosinophils inc.	Grade 0	34 (97.1%)	35 (97.2%)	33 (100.0%)
			Grade 1	1 (2.9%)	1 (2.8%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
	Placebo	Hb dec.	Grade 0	8 (100.0%)	8 (100.0%)	7 (87.5%)

Group	Arm	Diagnostic test	Severity	Day 0	Day 14	Day 28
			Grade 1	0 (0.0%)	0 (0.0%)	1 (12.5%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		WBC inc.	Grade 0	8 (100.0%)	8 (100.0%)	8 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		WBC dec.	Grade 0	8 (100.0%)	8 (100.0%)	7 (87.5%)
			Grade 1	0 (0.0%)	0 (0.0%)	1 (12.5%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Platelets dec.	Grade 0	8 (100.0%)	8 (100.0%)	8 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Neutrophils dec.	Grade 0	8 (100.0%)	8 (100.0%)	7 (87.5%)
			Grade 1	0 (0.0%)	0 (0.0%)	1 (12.5%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Lymphocytes dec.	Grade 0	8 (100.0%)	7 (87.5%)	6 (75.0%)
			Grade 1	0 (0.0%)	1 (12.5%)	2 (25.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Eosinophils inc.	Grade 0	8 (100.0%)	8 (100.0%)	8 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
2	ChAdOx1 MERS	Hb dec.	Grade 0	29 (90.6%)	29 (90.6%)	26 (86.7%)
			Grade 1	3 (9.4%)	2 (6.2%)	4 (13.3%)
			Grade 2	0 (0.0%)	1 (3.1%)	0 (0.0%)

Group	Arm	Diagnostic test	Severity	Day 0	Day 14	Day 28
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		WBC inc.	Grade 0	32 (100.0%)	32 (100.0%)	30 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		WBC dec.	Grade 0	31 (96.9%)	31 (96.9%)	30 (100.0%)
			Grade 1	1 (3.1%)	1 (3.1%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Platelets dec.	Grade 0	32 (100.0%)	32 (100.0%)	30 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Neutrophils dec.	Grade 0	31 (96.9%)	30 (93.8%)	27 (90.0%)
			Grade 1	1 (3.1%)	2 (6.2%)	3 (10.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Lymphocytes dec.	Grade 0	30 (93.8%)	31 (96.9%)	29 (96.7%)
			Grade 1	2 (6.2%)	1 (3.1%)	1 (3.3%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Eosinophils inc.	Grade 0	32 (100.0%)	32 (100.0%)	30 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
	Placebo	Hb dec.	Grade 0	5 (83.3%)	6 (100.0%)	4 (80.0%)
			Grade 1	1 (16.7%)	0 (0.0%)	1 (20.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)

Group	Arm	Diagnostic test	Severity	Day 0	Day 14	Day 28
		WBC inc.	Grade 0	6 (100.0%)	6 (100.0%)	5 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		WBC dec.	Grade 0	6 (100.0%)	6 (100.0%)	5 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Platelets dec.	Grade 0	6 (100.0%)	6 (100.0%)	5 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Neutrophils dec.	Grade 0	6 (100.0%)	6 (100.0%)	4 (80.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	1 (20.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Lymphocytes dec.	Grade 0	6 (100.0%)	6 (100.0%)	5 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)
		Eosinophils inc.	Grade 0	6 (100.0%)	6 (100.0%)	5 (100.0%)
			Grade 1	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 2	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 3	0 (0.0%)	0 (0.0%)	0 (0.0%)
			Grade 4	0 (0.0%)	0 (0.0%)	0 (0.0%)

3.4 SAEs and AESIs

Outcome measure	Evaluation Timepoints*
e) SAEs and AESIs	Whole duration of the study follow up period (D0 to V2+281)

Summary of SAEs

Group	Arm	Participants with ≥ 1 SAE	SAEs	Causality				AESI
				No relationship	Possible	Probable	Definite	
1	ChAdOx1 MERS (n=37)	0 (0%)	0	0/0	0/0	0/0	0/0	0
	Placebo (n=8)	1 (13%)	1	1/1 (100%)	0/1 (0%)	0/1 (0%)	0/1 (0%)	0
2	ChAdOx1 MERS (n=33)	3 (9%)	3	3/3 (100%)	0/3 (0%)	0/3 (0%)	0/3 (0%)	0
	Placebo (n=6)	0 (0%)	0	0/0	0/0	0/0	0/0	0
All (n=84)		4 (5%)	4	4/4 (100%)	0/4 (0%)	0/4 (0%)	0/4 (0%)	0

4. SECONDARY OUTCOMES

Outcome	Objective	Outcome measure	Evaluation Timepoints*
Secondary	To assess the immunogenicity of ChAdOx1 MERS vaccine in healthy adult volunteers aged 50-70	a) MERS spike protein specific serological response as measured by ELISA	D0, D14, D28, V2, V2+14, V2+28, V2+281
		b) MERS spike protein T cell response measured by IFN-γ ELISPOT	D0, D14, D28, V2, V2+14, V2+28, V2+281

One participant (MER-00330132; group 1 [ChAdOx1 nCoV-19 exposed] ChAdOx1 MERS) did not receive a second dose of study vaccine but had post-second vaccination samples taken and analysed. As the protocol states that all available data will be used in the analyses, the majority of data included in this section has been analysed using the modified intent-to-treat (mITT) population.

4.1 MERS spike protein specific serological response as measured by ELISA

Outcome measure	Evaluation Timepoints*
a) MERS spike protein specific serological response as measured by ELISA	D0, D14, D28, V2, V2+14, V2+28, V2+281

Humoral results

Geometric mean concentrations (GMCs) and their respective 95% CIs for the timepoints under evaluation are shown. Medians and inter-quartile range (IQR) of untransformed results are also presented at certain timepoints where high proportions (>30%) of all available results are below the lower limit of detection or quantification (LL).* ELISA results are presented in both ELISA Units (EU) and International Units (IU) calculated via direct conversion factor. Pseudoneutralising antibody (PNA) results are presented in both IC50 and IU calculated via the internal control of the assay.

LLs:

MERS ELISA: 220 EU, 14.51 IU (LLOQ)

MERS PNA: 50 IC50, 38.1 IU (LLOD)

Anti-ChAdOx1 spike: 43.75 AU*DF (arbitrary units * dilution factor) (LLOD)

Anti-SARS-CoV-2 spike: 13 EU (LLOQ)

SARS-CoV-2 PNA: 50 IC50 (LLOD)

Anti-spike MERS ELISA (EU) results

Timepoint (days)	GMC (95% CI) *median (IQR)*[1]			
	Group 1: ChAdOx1 nCoV-19 exposed		Group 2: ChAdOx1 nCoV-19 naïve	
	ChAdOx1 MERS	Placebo	ChAdOx1 MERS	Placebo
0	148.31 (120.26, 182.91) *110.00 (110.00-110.00)* [n=37]	210.81 (75.12, 591.54) *110.00 (110.00-503.23)* [n=7]	143.80 (115.86, 178.47) *110.00 (110.00-110.00)* [n=33]	110.00 (110.00, 110.00) *110.00 (110.00-110.00)* [n=6]
14	230.42 (173.06, 306.80) *110.00 (110.00-464.11)* [n=37]	219.24 (88.75, 541.60) *110.00 (110.00-417.56)* [n=8]	368.17 (258.66, 524.04) *416.57 (110.00-800.77)* [n=33]	110.00 (110.00, 110.00) *110.00 (110.00-110.00)* [n=6]
28	417.86 (286.36, 609.76) [n=36]	272.22 (107.84, 687.15) [n=8]	1168.30 (829.77, 1644.96) [n=31]	110.00 (110.00, 110.00) [n=6]
84 (V2)	370.39 (259.19, 529.30) [n=35]	249.64 (102.98, 605.15) [n=8]	864.42 (606.65, 1231.71) [n=32]	128.44 (86.23, 191.31) [n=6]
98 (V2+14)	3071.99 (2084.66, 4526.94) [n=35]	219.19 (90.55, 530.54) [n=8]	7943.65 (5494.76, 11483.94) [n=30]	110.00 (110.00, 110.00) [n=6]
112 (V2+28)	3518.51 (2375.26, 5212.04) [n=33]	199.64 (79.20, 503.21) [n=8]	8453.39 (6084.46, 11744.66) [n=30]	110.00 (110.00, 110.00) [n=5]
365 (V2+281)	599.50 (398.34, 902.25) [n=35]	190.16 (81.46, 443.89) [n=8]	1522.98 (1070.89, 2165.91) [n=30]	156.23 (63.40, 384.95) [n=6]

[1]Medians and IQR of untransformed results presented at timepoints where >30% of results are below the LL

Anti-spike MERS ELISA (IU) results

Timepoint (days)	GMC (95% CI) *median (IQR)*[1]			
	Group 1: ChAdOx1 nCoV-19 exposed		Group 2: ChAdOx1 nCoV-19 naïve	
	ChAdOx1 MERS	Placebo	ChAdOx1 MERS	Placebo
0	9.78 (7.93, 12.06) *7.26 (7.26-7.26)* [n=37]	13.90 (4.95, 39.01) *7.26 (7.26-33.19)* [n=7]	9.48 (7.64, 11.77) *7.26 (7.26-7.26)* [n=33]	7.26 (7.26, 7.26) *7.26 (7.26-7.26)* [n=6]
14	15.20 (11.41, 20.23) *7.26 (7.26-30.61)* [n=37]	14.46 (5.85, 35.72) *7.26 (7.26-27.54)* [n=8]	24.28 (17.06, 34.56) *27.47 (7.26-52.81)* [n=33]	7.26 (7.26, 7.26) *7.26 (7.26-7.26)* [n=6]
28	27.56 (18.89, 40.22) [n=36]	17.95 (7.11, 45.32) [n=8]	77.05 (54.73, 108.49) [n=31]	7.26 (7.26, 7.26) [n=6]
84 (V2)	24.43 (17.09, 34.91) [n=35]	16.46 (6.79, 39.91) [n=8]	57.01 (40.01, 81.24) [n=32]	8.47 (5.69, 12.62) [n=6]
98 (V2+14)	202.61 (137.49, 298.57) [n=35]	14.46 (5.97, 34.99) [n=8]	523.92 (362.40, 757.42) [n=30]	7.26 (7.26, 7.26) [n=6]
112 (V2+28)	232.06 (156.66, 343.76) [n=33]	13.17 (5.22, 33.19) [n=8]	557.54 (401.30, 774.61) [n=30]	7.26 (7.26, 7.26) [n=5]
365 (V2+281)	39.54 (26.27, 59.51) [n=35]	12.54 (5.37, 29.28) [n=8]	100.45 (70.63, 142.85) [n=30]	10.30 (4.18, 25.39) [n=6]

[1]Medians and IQR of untransformed results presented at timepoints where >30% of results are below the LL

Anti-spike MERS ELISA seroconversion

Seroconversion has been defined as at least a 4-fold rise in antibody levels between D0 and the timepoint of interest among participants with detectable antibody levels at D0 (i.e. ≥LL), or detectable antibody levels at the timepoint of interest among participants with no D0 detectable levels (i.e. <LL).

Data has been analysed using both the mITT and per-protocol (PP) population. The PP population excludes post-vaccination samples from participants not receiving the corresponding allocated vaccination (i.e. excludes the post-second dose samples from MER-00330132).

Timepoint (days)	Group		Seroconversion (95% CI)	
			mITT population	PP population
14	1: ChAdOx1 nCoV-19 exposed	ChAdOx1 MERS	11/37; 29.7% (15.9%, 47.0%)	11/37; 29.7% (15.9%, 47.0%)
		Placebo	1/7; 14.3% (0.4%, 57.9%)	1/7; 14.3% (0.4%, 57.9%)
	2: ChAdOx1 nCoV-19 naïve	ChAdOx1 MERS	18/33; 54.5% (36.4%, 71.9%)	18/33; 54.5% (36.4%, 71.9%)
		Placebo	0/6; 0.0% (0.0%, 45.9%)	0/6; 0.0% (0.0%, 45.9%)
28	1: ChAdOx1 nCoV-19 exposed	ChAdOx1 MERS	17/36; 47.2% (30.4%, 64.5%)	17/36; 47.2% (30.4%, 64.5%)
		Placebo	2/7; 28.6% (3.7%, 71.0%)	2/7; 28.6% (3.7%, 71.0%)
	2: ChAdOx1 nCoV-19 naïve	ChAdOx1 MERS	28/31; 90.3% (74.2%, 98.0%)	28/31; 90.3% (74.2%, 98.0%)
		Placebo	0/6; 0.0% (0.0%, 45.9%)	0/6; 0.0% (0.0%, 45.9%)
98 (V2+14)	1: ChAdOx1 nCoV-19 exposed	ChAdOx1 MERS	34/35; 97.1% (85.1%, 99.9%)	34/34; 100.0% (89.7%, 100.0%)
		Placebo	1/7; 14.3% (0.4%, 57.9%)	1/7; 14.3% (0.4%, 57.9%)
	2: ChAdOx1 nCoV-19 naïve	ChAdOx1 MERS	30/30; 100.0% (88.4%, 100.0%)	30/30; 100.0% (88.4%, 100.0%)
		Placebo	0/6; 0.0% (0.0%, 45.9%)	0/6; 0.0% (0.0%, 45.9%)
112 (V2+28)	1: ChAdOx1 nCoV-19 exposed	ChAdOx1 MERS	31/33; 93.9% (79.8%, 99.3%)	31/33; 93.9% (79.8%, 99.3%)
		Placebo	0/7; 0.0% (0.0%, 41.0%)	0/7; 0.0% (0.0%, 41.0%)
	2: ChAdOx1 nCoV-19 naïve	ChAdOx1 MERS	30/30; 100.0% (88.4%, 100.0%)	30/30; 100.0% (88.4%, 100.0%)
		Placebo	0/5; 0.0% (0.0%, 52.2%)	0/5; 0.0% (0.0%, 52.2%)
365 (V2+281)	1: ChAdOx1 nCoV-19 exposed	ChAdOx1 MERS	23/35; 65.7% (47.8%, 80.9%)	23/34; 67.6% (49.5%, 82.6%)
		Placebo	0/7; 0.0% (0.0%, 41.0%)	0/7; 0.0% (0.0%, 41.0%)
	2: ChAdOx1 nCoV-19 naïve	ChAdOx1 MERS	28/30; 93.3% (77.9%, 99.2%)	28/30; 93.3% (77.9%, 99.2%)
		Placebo	1/6; 16.7% (0.4%, 64.1%)	1/6; 16.7% (0.4%, 64.1%)

Geometric mean fold-rise (GMFR) results

Antibody	Timepoints	GMFR (95% CI)			
		Group 1: ChAdOx1 nCoV-19 exposed		Group 2: ChAdOx1 nCoV-19 naïve	
		ChAdOx1 MERS	Placebo	ChAdOx1 MERS	Placebo
Anti-spike MERS (EU)	V2+28/D28	8.36 (5.60, 12.47) [n=32]	0.73 (0.47, 1.14) [n=8]	7.49 (5.21, 10.77) [n=30]	1.00 (1.00, 1.00) [n=5]
	V2+28/V2	9.54 (6.35, 14.34) [n=33]	0.80 (0.56, 1.15) [n=8]	9.69 (6.86, 13.68) [n=30]	0.83 (0.50, 1.39) [n=5]
	V2+281/V2	1.70 (1.23, 2.35) [n=34]	0.76 (0.55, 1.05) [n=8]	1.64 (1.24, 2.17) [n=30]	1.22 (0.42, 3.50) [n=6]

4.2 MERS spike protein T cell response measured by IFN-γ ELISPOT

Outcome measure	Evaluation Timepoints*
b) MERS spike protein T cell response measured by IFN-γ ELISPOT	D0, D14, D28, V2, V2+14, V2+28, V2+281

ELISpot results (SFC/10^6 PBMCs)

Medians and inter-quartile range (IQR) of untransformed results for the timepoints under evaluation are shown in the table below.

Timepoint (days)	Median (IQR)			
	Group 1: ChAdOx1 nCoV-19 exposed		Group 2: ChAdOx1 nCoV-19 naïve	
	ChAdOx1 MERS	Placebo	ChAdOx1 MERS	Placebo
0	169 (82-319) [n=22]	168 (128-321) [n=7]	154 (97-262) [n=22]	295 (263-313) [n=3]
14	424 (272-1269) [n=31]	261 (81-426) [n=8]	1566 (484-2188) [n=31]	165 (115-535) [n=4]
28	414 (261-908) [n=34]	215 (130-346) [n=8]	1185 (573-1912) [n=32]	177 (108-365) [n=6]
84 (V2)	222 (123-317) [n=30]	265 (52-293) [n=7]	577 (322-1587) [n=32]	118 (79-149) [n=6]
98 (V2+14)	366 (157-698) [n=35]	295 (69-404) [n=7]	1125 (512-2290) [n=30]	182 (127-251) [n=6]
112 (V2+28)	240 (130-359) [n=32]	195 (178-216) [n=8]	904 (552-2538) [n=30]	180 (96-224) [n=5]
365 (V2+281)	187 (123-404) [n=35]	199 (102-283) [n=8]	426 (209-1120) [n=28]	223 (68-277) [n=6]